"Deoxycytidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE.
Descriptor ID |
D003841
|
MeSH Number(s) |
D03.383.742.680.245.500 D13.570.230.329 D13.570.685.245.500
|
Concept/Terms |
Deoxycytidine- Deoxycytidine
- Cytosine Deoxyribonucleoside
- Deoxyribonucleoside, Cytosine
- Cytosine Deoxyriboside
- Deoxyriboside, Cytosine
|
Below are MeSH descriptors whose meaning is more general than "Deoxycytidine".
Below are MeSH descriptors whose meaning is more specific than "Deoxycytidine".
This graph shows the total number of publications written about "Deoxycytidine" by people in this website by year, and whether "Deoxycytidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 0 | 1 |
2005 | 2 | 0 | 2 |
2006 | 0 | 1 | 1 |
2007 | 1 | 0 | 1 |
2008 | 0 | 2 | 2 |
2009 | 1 | 0 | 1 |
2010 | 0 | 4 | 4 |
2011 | 0 | 3 | 3 |
2012 | 1 | 3 | 4 |
2013 | 4 | 3 | 7 |
2014 | 2 | 5 | 7 |
2015 | 1 | 0 | 1 |
2016 | 2 | 0 | 2 |
2017 | 2 | 0 | 2 |
2018 | 3 | 3 | 6 |
2020 | 1 | 1 | 2 |
2021 | 1 | 1 | 2 |
2022 | 0 | 3 | 3 |
2023 | 0 | 2 | 2 |
2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Deoxycytidine" by people in Profiles.
-
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. J Clin Oncol. 2025 Feb 10; 43(5):536-544.
-
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4932-4942.
-
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone Marrow Transplant. 2024 Dec; 59(12):1754-1762.
-
Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group. ESMO Open. 2024 Sep; 9(9):103689.
-
Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Ann Oncol. 2024 Dec; 35(12):1181-1190.
-
Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study. Cancer Biol Med. 2024 Jul 26; 21(9).
-
BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism. Sci Adv. 2024 Jun 21; 10(25):eadj8650.
-
Tumor-derived interleukin 35 mediates the dissemination of gemcitabine resistance in pancreatic adenocarcinoma. Oncogene. 2024 03; 43(11):776-788.
-
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
-
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2024 Feb; 21(2):101-124.